Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Nov 15;1:16017. doi: 10.1038/npjvaccines.2016.17

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2016 The Author(s)

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

Immunogenicity of CPSXiv-CRM₁₉₇ in comparison with CPSXn-CRM₁₉₇. (a) Vaccination schedule showing the immunisation and bleeding of mice. (b) The anti-CPSX IgG ELISA used to determine immunisation results demonstrated comparable IgG responses to CPSX with both, the synthetic (CPSXiv-CRM₁₉₇) and the benchmark (CPSXn-CRM₁₉₇) vaccine. Each symbol represents an individual animal. The horizontal bars indicate the geometric mean titre and 95% confidence intervals. *Significant differences between the indicated groups with P<0.05 (CPSXn-CRM¹⁹⁷: P=0.028, CPSXiv-CRM¹⁹⁷: P=0.0284; Mann-Whitney test). CPSX, NmX capsule polysaccharide; CPSXiv, in vitro produced CPSX; CPSXn, CPSX obtained from natural source; IgG, immunoglobulin G.